Key result
Pim-1 reduces myofilament Ca2+ sensitivity via cTnI phosphorylation, implicating its downregulation in diabetic cardiomyopathy.
Why the study?
Does Pim-1 kinase phosphorylate cTnI and regulate myofilament function in cardiomyocytes?
Does Pim-1 kinase phosphorylate cTnI and regulate myofilament function in cardiomyocytes?
Pim-1 is a novel kinase for cTnI, and its downregulation in diabetes may contribute to diabetic cardiomyopathy, highlighting a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
Pim-1 may modulate myofilament Ca2+ sensitivity in diabetic models; leaves open human validation and therapeutic targeting.
BACKGROUND/AIMS: Pim-1 is a serine/threonine kinase that is highly expressed in the heart, and exerts potent cardiac protective effects through enhancing survival, proliferation, and regeneration of cardiomyocytes. Its myocardial specific substrates, however, remain unknown. In the present study, we aim to investigate whether Pim-1 modulates myofilament activity through phosphorylation of cardiac troponin I (cTnI), a key component in regulating myofilament function in the heart. METHODS: Coimmunoprecipitation and immunofluorescent assays were employed to investigate the interaction of Pim-1 with cTnI in cardiomyocytes. Biochemical, site directed mutagenesis, and mass spectrometric analyses were utilized to identify the phosphorylation sites of Pim1 in cTnI. Myofilament functional assay using skinned cardiac fiber was used to assess the effect of Pim1-mediated phosphorylation on cardiac myofilament activity. Lastly, the functional significance of Pim1-mediated cTnI in heart disease was determined in diabetic mice. RESULTS: We found that Pim-1 specifically interacts with cTnI in cardiomyocytes and this interaction leads to Pim1-mediated cTnI phosphorylation, predominantly at Ser23/24 and Ser150. Furthermore, our functional assay demonstrated that Pim-1 induces a robust phosphorylation of cTnI within the troponin complex, thus leading to a decreased Ca2+ sensitivity. Insulin-like growth factor 1 (IGF-1), a peptide growth factor that has been shown to stimulate myocardial contractility, markedly induces cTnI phosphorylation at Ser23/24 and Ser150 through increasing Pim-1 expression in cardiomyocytes. In a high-fat diabetic mice model, the expression of Pim1 in the heart is significantly decreased, which is accompanied by a decreased phosphorylation of cTnI at Ser23/24 and Ser150, further implicating the pathological significance of the Pim1/cTnI axis in the development of diabetic cardiomyopathy. CONCLUSION: Our results demonstrate that Pim-1 is a novel kinase that phosphorylates cTnI primarily at Ser23/24 and Ser150 in cardiomyocytes, which in turn may modulate myofilament function under a variety of physiological and pathophysiological conditions.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2018) studied Diabetic cardiomyopathy (preclinical model). Pim-1 kinase vs. Control was evaluated on pCa at 50% maximal tension (pCa50) (p=<0.05). Pim-1 phosphorylates cTnI primarily at Ser23/24 and Ser150, leading to decreased myofilament Ca2+ sensitivity, and its downregulation is implicated in diabetic cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: